{"id":"https://openalex.org/W2128034652","doi":"https://doi.org/10.1177/1932296815583059","title":"Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Na\u00efve Patients With Type 2 Diabetes","display_name":"Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Na\u00efve Patients With Type 2 Diabetes","alternate_titles":[],"publication_year":2015,"publication_date":"2015-04-21","ids":{"openalex":"https://openalex.org/W2128034652","doi":"https://doi.org/10.1177/1932296815583059","mag":"2128034652","pmid":"https://pubmed.ncbi.nlm.nih.gov/25901022","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4667342"},"language":"en","primary_location":{"id":"doi:10.1177/1932296815583059","doi":"https://doi.org/10.1177/1932296815583059","is_oa":true,"landing_page_url":"https://doi.org/10.1177/1932296815583059","pdf_url":"https://journals.sagepub.com/doi/pdf/10.1177/1932296815583059","source":{"id":"https://openalex.org/S2754852731","display_name":"Journal of Diabetes Science and Technology","issn_l":"1932-2968","issn":["1932-2968","1932-3107"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Diabetes Science and Technology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2128034652"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://journals.sagepub.com/doi/pdf/10.1177/1932296815583059","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032661408","display_name":"Glenn Matfin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Glenn Matfin","raw_affiliation_strings":["International Diabetes Center, Minneapolis, MN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"International Diabetes Center, Minneapolis, MN, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080408619","display_name":"Kate Van Brunt","orcid":"https://orcid.org/0009-0007-9738-8302","observed_orcids":["https://orcid.org/0009-0007-9738-8302"]},"institutions":[{"id":"https://openalex.org/I4210095227","display_name":"Eli Lilly (United Kingdom)","ror":"https://ror.org/00psab413","country_code":"GB","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095227"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kate Van Brunt","raw_affiliation_strings":["Eli Lilly and Company, Windlesham, Surrey, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Windlesham, Surrey, UK","institution_ids":["https://openalex.org/I4210095227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113170261","display_name":"Alan G. Zimmermann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alan G. Zimmermann","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075118496","display_name":"Rebecca J. Threlkeld","orcid":"https://orcid.org/0009-0002-7214-4065","observed_orcids":["https://orcid.org/0009-0002-7214-4065"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rebecca Threlkeld","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021245924","display_name":"Debra A. Ignaut","orcid":"https://orcid.org/0000-0002-0449-9393","observed_orcids":["https://orcid.org/0000-0002-0449-9393"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Debra A. Ignaut","raw_affiliation_strings":["Eli Lilly and Company; Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company; Indianapolis, IN USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5021245924"],"corresponding_institution_ids":["https://openalex.org/I168537998"],"apc_list":{"value":3900,"currency":"USD","value_usd":3900},"apc_paid":null,"fwci":5.3749,"has_fulltext":true,"cited_by_count":54,"citation_normalized_percentile":{"value":0.96758737,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"9","issue":"5","first_page":"1071","last_page":"1079"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.7080000042915344,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.7080000042915344,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.23499999940395355,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10793","display_name":"Diabetes Management and Education","score":0.03929999843239784,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dulaglutide","display_name":"dulaglutide","score":0.9940000176429749},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9259999990463257},{"id":"https://openalex.org/keywords/self-injection","display_name":"self-injection","score":0.7749999761581421},{"id":"https://openalex.org/keywords/injection-success-rate","display_name":"injection success rate","score":0.796999990940094},{"id":"https://openalex.org/keywords/diabetes-self-management","display_name":"diabetes self-management","score":0.5460000038146973},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.75},{"id":"https://openalex.org/keywords/injection-pain","display_name":"injection pain","score":0.47600001096725464},{"id":"https://openalex.org/keywords/device-satisfaction","display_name":"device satisfaction","score":0.5809999704360962},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.5960000157356262},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.6620000004768372},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.35199999809265137},{"id":"https://openalex.org/keywords/patient-satisfaction","display_name":"patient satisfaction","score":0.3059999942779541}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9076012372970581},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5587418079376221},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.46418777108192444},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.4334952235221863},{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.4315505027770996},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3519378900527954},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2983831465244293},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.251945436000824},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.14164498448371887},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017060","descriptor_name":"Patient Satisfaction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057240","descriptor_name":"Patient Preference","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1177/1932296815583059","doi":"https://doi.org/10.1177/1932296815583059","is_oa":true,"landing_page_url":"https://doi.org/10.1177/1932296815583059","pdf_url":"https://journals.sagepub.com/doi/pdf/10.1177/1932296815583059","source":{"id":"https://openalex.org/S2754852731","display_name":"Journal of Diabetes Science and Technology","issn_l":"1932-2968","issn":["1932-2968","1932-3107"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Diabetes Science and Technology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4667342","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4667342/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Diabetes Sci Technol","raw_type":"Text"},{"id":"pmid:25901022","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25901022","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of diabetes science and technology","raw_type":"Clinical Trial"}],"best_oa_location":{"id":"doi:10.1177/1932296815583059","doi":"https://doi.org/10.1177/1932296815583059","is_oa":true,"landing_page_url":"https://doi.org/10.1177/1932296815583059","pdf_url":"https://journals.sagepub.com/doi/pdf/10.1177/1932296815583059","source":{"id":"https://openalex.org/S2754852731","display_name":"Journal of Diabetes Science and Technology","issn_l":"1932-2968","issn":["1932-2968","1932-3107"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Diabetes Science and Technology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2128034652.pdf","grobid_xml":"https://content.openalex.org/works/W2128034652.grobid-xml"},"referenced_works_count":25,"referenced_works":["https://openalex.org/W29426176","https://openalex.org/W1971331161","https://openalex.org/W1986252859","https://openalex.org/W1989116954","https://openalex.org/W2000376961","https://openalex.org/W2001756472","https://openalex.org/W2017534125","https://openalex.org/W2020195043","https://openalex.org/W2028371970","https://openalex.org/W2057052260","https://openalex.org/W2070309137","https://openalex.org/W2071438133","https://openalex.org/W2072093923","https://openalex.org/W2077144795","https://openalex.org/W2084822528","https://openalex.org/W2103829708","https://openalex.org/W2106578604","https://openalex.org/W2108178305","https://openalex.org/W2116922757","https://openalex.org/W2137834479","https://openalex.org/W2149896325","https://openalex.org/W2155990793","https://openalex.org/W2158137823","https://openalex.org/W2161983652","https://openalex.org/W2166506604"],"related_works":["https://openalex.org/W2082239818","https://openalex.org/W2791793704","https://openalex.org/W2067076667","https://openalex.org/W2778657237","https://openalex.org/W2521600716","https://openalex.org/W2765923679","https://openalex.org/W2120886606","https://openalex.org/W1995693115","https://openalex.org/W3154815729","https://openalex.org/W2083895854"],"abstract_inverted_index":{"BACKGROUND:":[0],"This":[1],"4-week,":[2],"phase":[3],"3b,":[4],"multicenter,":[5],"open-label,":[6],"single-arm,":[7],"outpatient":[8],"study":[9,268],"demonstrated":[10],"the":[11,17,60,75,80,84,96,99,111,118,124,150,155,158,170,180,190,211,224,233,241,251,255,278],"safe":[12,290],"and":[13,48,65,69,93,104,123,157,177,243,291,313],"effective":[14,292],"use":[15,176,250,295],"of":[16,24,59,63,144,169,175,201,273],"dulaglutide":[18,282],"single-dose":[19,76,171,252,283],"pen":[20,253,284],"containing":[21],"0.5":[22],"mL":[23],"placebo":[25],"for":[26,89,98,109,294,311],"subcutaneous":[27],"injection":[28,198,213,305],"in":[29,270],"injection-na\u00efve":[30],"adult":[31],"patients":[32,153,185,230,297,312],"with":[33,38,74,179,195,240,298],"type":[34],"2":[35,90],"diabetes":[36],"(T2D),":[37],"A1C":[39],"\u2264":[40,49],"8.5%":[41],"(69":[42],"mmol/mol),":[43],"BMI":[44],"\u2265":[45],"23":[46],"kg/m2":[47],"45":[50],"kg/m(2).":[51],"METHOD:":[52],"Patients":[53,78,140],"completed":[54,79,154],"a":[55,196,259,289],"modified":[56],"self-injecting":[57],"subscale":[58],"Diabetes":[61],"Fear":[62],"Injecting":[64],"Self-Testing":[66],"Questionnaire":[67],"(mD-FISQ)":[68],"were":[70,107,238,301],"trained":[71],"to":[72,95,129,165,206,221,236,247,249,267,287],"self-inject":[73],"pen.":[77],"initial":[81,103,212],"self-injection":[82,114],"at":[83,87],"site,":[85],"injected":[86],"home":[88],"subsequent":[91],"weeks,":[92],"returned":[94],"site":[97],"final":[100,105,112,151,197],"injection.":[101,148],"The":[102,281],"self-injections":[106],"evaluated":[108],"success;":[110],"(initial)":[113],"success":[115,132,199,214],"rate":[116,133,200,215],"was":[117,128,193,216,258,285],"primary":[119,125,191],"(secondary)":[120,126],"outcome":[121],"measure,":[122],"objective":[127,192],"demonstrate":[130],"this":[131],"as":[134,275],"being":[135],"significantly":[136],"greater":[137],"than":[138],"80%.":[139],"recorded":[141],"their":[142,167],"level":[143],"pain":[145],"after":[146,254],"each":[147],"After":[149],"injection,":[152],"mD-FISQ":[156],"Medication":[159],"Delivery":[160],"Device":[161],"Assessment":[162],"Battery":[163],"(MDDAB)":[164],"assess":[166],"perceptions":[168],"pen,":[172],"including":[173],"ease":[174],"experience":[178,306],"device.":[181],"RESULTS:":[182],"Among":[183,208],"211":[184],"(mean":[186],"age:":[187],"61":[188],"years),":[189],"met,":[194],"99.1%":[202],"(95%":[203,218],"CI:":[204,219],"96.6%":[205],"99.7%).":[207],"214":[209],"patients,":[210],"97.2%":[217],"94.0%":[220],"98.7%),":[222],"meeting":[223],"key":[225],"secondary":[226],"objective.":[227],"Overall,":[228],"most":[229],"(>96%)":[231],"found":[232,286],"device":[234,293],"easy":[235],"use,":[237],"satisfied":[239],"device,":[242],"would":[244],"be":[245,288],"willing":[246],"continue":[248],"study.":[256],"There":[257],"significant":[260],"reduction":[261],"(P":[262],"<":[263],".001)":[264],"from":[265],"baseline":[266],"end":[269],"patients'":[271],"fear":[272],"self-injecting,":[274],"measured":[276],"by":[277,296],"mD-FISQ.":[279],"CONCLUSIONS:":[280],"T2D":[299],"who":[300],"injection-na\u00efve.":[302],"A":[303],"positive":[304],"is":[307],"an":[308],"important":[309],"factor":[310],"providers":[314],"when":[315],"initiating":[316],"injectable":[317],"therapy.":[318]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2128034652","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
